Ericksen Scott D sold $58K of ILMN

Ericksen Scott D (VP, Chief Accounting Officer) sold 267 shares of ILLUMINA, INC. (ILMN) at $217.76 on 2026-11-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ericksen Scott D
Published Nov 12, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially, but it adds to the flow of insider activity data that traders monitor.

02

Market read

A small insider sell; minimal immediate impact but useful for monitoring insider sentiment.

03

What to watch

The insider retains a large stake (14,029 shares) and the sale was pre‑arranged under a 10b5‑1 plan.

Relevance 2/10Novelty 2/10Timing: after-hours filing

Background

Illumina is a leading provider of sequencing and genomic analysis tools. Insider transactions are regularly disclosed via Form 4.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

SEC Form 4 shows VP and CFO Ericksen Scott D sold 267 shares of Illumina at $217.76, a $58K transaction.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to total holdings and recent price, but insider sales can prompt short‑term downside bias.

Market effects

None significant for the genomics sector.

No regional effect.

Limited to Illumina investors.

Counterpoint

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Illumina, Inc.

    US‑listed genomics company (ticker ILMN).

  • Ericksen Scott D

    Vice President, Chief Accounting Officer at Illumina.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.